Show simple item record

AuthorTaylor, Hori
AuthorOwusu, Yaw B.
AuthorSun, Dianqing
Available date2023-12-26T08:55:16Z
Publication Date2022-12-31
Publication NameEncyclopedia of Infection and Immunity
Identifierhttp://dx.doi.org/10.1016/B978-0-12-818731-9.00144-0
ISBN9780323903035
URIhttps://www.sciencedirect.com/science/article/pii/B9780128187319001440
URIhttp://hdl.handle.net/10576/50633
AbstractThere is an urgent need to develop new antibiotics for the treatment of difficult-to-treat bacterial infections, caused by pathogens such as Mycobacterium tuberculosis, Gram-positive methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and Clostridioides difficile, Gram-negative Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae (CRE), as well as multi-drug resistant Acinetobacter baumannii and Neisseria gonorrhoeae. Thirty-five antibiotics have been approved by US FDA since 2000. These new antibiotics include new chemotype antibacterial classes such as oxazolidinone (linezolid and tedizolid phosphate), lipocyclopeptide (daptomycin), anti-difficile macrolide (fidaxomicin), the cephalosporin-siderophore conjugate antibiotic (cefiderocol), and antitubercular agents diarylquinoline and nitroimidazooxazine (bedaquiline and PA-824, respectively). The remaining advanced antibiotics, developed on the basis of existing antibacterial chemical classes, include carbapenem (ertapenem and doripenem), nitroimidazoles (tinidazole and secnidazole), fluoroquinolones (gemifloxacin mesylate, besifloxacin, delafloxacin, and finafloxacin), ketolide (telithromycin), rifamycin (rifaximin and rifamycin SV), tetracycline and/or glycylcycline (tigecycline, eravacycline, omadacycline, and sarecycline), pleuromutilins (retapamulin and lefamulin), lipoglycopeptides (telavancin, oritavancin, and dalbavancin), cephalosporin (ceftaroline fosamil), aminoglycoside (plazomicin), four β-lactam/β-lactamase inhibitor combinations (ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, and imipenem/cilastatin/relebactam with a renal dehydropeptidase inhibitor), along with three monoclonal antibodies (mAbs) (raxibacumab, obiltoxaximab, and bezlotoxumab). The chemical class, physiochemical property, mechanism of action, route of administration and dosing frequency, pharmacokinetic profiles (e.g., Tmax, t1/2, bioavailability, protein binding, metabolism, excretion, etc.), as well as clinical indications and adverse effects of each antibiotic are reviewed and discussed in detail.
Languageen
PublisherElsevier
SubjectBedaquiline
Besifloxacin
Bezlotoxumab
Cefiderocol
Ceftaroline fosamil
Ceftazidime/avibactam
Ceftobiprole medocaril
Ceftolozane/tazobactam
Dalbavancin
Daptomycin
Delafloxacin
Doripenem
Eravacycline
Ertapenem
Fidaxomicin
Finafloxacin
Gemifloxacin
Imipenem/cilastatin/relebactam
Lefamulin
Linezolid
Meropenem/vaborbactam
Obiltoxaximab
Omadacycline
Oritavancin
Plazomicin
Pretomanid
Raxibacumab
Retapamulin
Rifamycin SV
Rifaximin
Sarecycline
Secnidazole
Tedizolid phosphate
Telavancin
Telithromycin
Tigecycline
Tinidazole
TitleUS FDA-Approved Antibiotics During the 21st Century
TypeBook chapter
Pagination556-585
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record